Search

Zentalis Pharmaceuticals Inc

Slēgts

4.88 2.95

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.52

Max

4.92

Galvenie mērījumi

By Trading Economics

Ienākumi

-136K

-35M

EPS

-0.503

Darbinieki

106

EBITDA

2.2M

-35M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+36.17% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 4. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

41M

336M

Iepriekšējā atvēršanas cena

1.93

Iepriekšējā slēgšanas cena

4.88

Zentalis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 9. jūl. 23:56 UTC

Event

United Airlines shares are higher in after-market trading ahead of its Q2 FY2026 earnings announcement, with EPS expected at $1.81 and revenue at $17.6 billion.

2026. g. 9. jūl. 23:56 UTC

Incyte Corp shares are lower in after-market hours amid broader market caution linked to renewed military tensions between the U.S. and Iran.

2026. g. 9. jūl. 23:56 UTC

Social Media
News

NVIDIA Corp shares are lower in after-market trading amid concerns about its AI sector performance and intensifying competition from other chip manufacturers.

2026. g. 9. jūl. 23:56 UTC

ETF Constituents
Macro News
Correlated Moves

The VanEck Gold Miners ETF rose in after-market hours amid positive sentiment for gold mining assets and a drop in crude oil prices.

2026. g. 9. jūl. 23:52 UTC

Correlated Moves

The iShares TIPS Bond ETF is trading lower in after-market hours, reflecting broader market sentiment and remaining below its 20-day moving average.

2026. g. 9. jūl. 23:51 UTC

Ross Stores Inc. shares are lower in after-market hours, declining since Thursday's close and remaining below the 20-day moving average.

2026. g. 9. jūl. 23:51 UTC

Fox Corp shares are higher in after-market hours, despite remaining below their 20-day moving average amid broader market fluctuations and declining jobless claims.

2026. g. 9. jūl. 23:51 UTC

U.S. equity markets remain flat amid geopolitical tensions and mixed economic signals, while Treasury yields decline and tech stocks show resilience.

2026. g. 9. jūl. 23:51 UTC

Global equity markets rise, led by Asia, while U.S. indices remain flat amid mixed economic data and geopolitical tensions; jobless claims drop unexpectedly but home sales decline raises housing market concerns.

2026. g. 9. jūl. 23:51 UTC

European equity markets rise on strong German export data and easing geopolitical tensions, while bond yields increase amid inflation concerns.

2026. g. 9. jūl. 23:51 UTC

Asia equity markets rise amid geopolitical tensions, while China's vehicle sales decline and Japan's machine tool orders soar, as U.S. jobless claims drop unexpectedly.

2026. g. 9. jūl. 23:51 UTC

Brazil's Retail Sales Report on July 16 Expected to Show Recovery After April Decline, Boosting Economic Sentiment Amid Global Uncertainties.

2026. g. 9. jūl. 23:51 UTC

Regeneron Pharmaceuticals Inc shares are lower in after-market hours following a weak trading session, despite a report showing a decrease in initial jobless claims.

2026. g. 9. jūl. 23:51 UTC

Correlated Moves
ETF Constituents
Macro News

Vanguard Real Estate ETF gained after-market hours, supported by easing crude oil prices and positive sentiment from potential diplomatic resolutions between Iran and the U.S.

2026. g. 9. jūl. 23:51 UTC

News
Social Media

Meta Platforms Inc. shares advanced in after-market trading following the launch of Muse Spark 1.1, an AI model aimed at enhancing software development capabilities.

2026. g. 9. jūl. 23:51 UTC

Social Media
News

Netflix is exploring strategies to boost subscriber engagement amid declining viewer interest. Shares fell in after-hours trading following these developments.

2026. g. 9. jūl. 23:46 UTC

Sirius XM Holdings Inc shares are lower in after-market trading. No specific news was identified to explain the price movement.

2026. g. 9. jūl. 23:46 UTC

Biogen Inc shares are trading lower in after-market hours, continuing a trend of five consecutive daily declines without any specific news to explain the movement.

2026. g. 9. jūl. 23:46 UTC

News

The United States Oil Fund LP is trading lower in after-market hours, reflecting ongoing geopolitical tensions and a flat trajectory since Thursday's close.

2026. g. 9. jūl. 23:42 UTC

Upcoming U.S. CPI Release on July 14, 2026, Expected to Reflect Rising Inflation Pressures Amidst Food Price Concerns and Geopolitical Tensions Impacting Energy Costs.

2026. g. 9. jūl. 23:42 UTC

Core Inflation Rate YoY for June 2026 set to release on July 14, with a forecast of 2.9%, amid rising inflation concerns and cautious market sentiment regarding potential interest rate hikes.

2026. g. 9. jūl. 23:42 UTC

Core Inflation Rate MoM for June 2026 set to rise by 0.3% amid geopolitical tensions and surging oil prices, impacting investor sentiment ahead of the report release on July 14.

2026. g. 9. jūl. 23:42 UTC

CPI Release on July 14, 2026 Sparks Caution Among Investors Amid Rising Inflation and Geopolitical Tensions.

2026. g. 9. jūl. 23:42 UTC

U.S. Inflation Rate Expected to Rise Amidst Economic Pressures and Consumer Behavior Shifts, Set for Release on July 14, 2026

2026. g. 9. jūl. 23:42 UTC

U.S. June Inflation Rate Release on July 14 Expected to Show Slight Decrease Amid Geopolitical Tensions and Economic Uncertainty

2026. g. 9. jūl. 23:41 UTC

ETF Constituents

After-market trading for iShares MSCI South Korea ETF is near unchanged, with SK Telecom Co. contributing a return of 0.67%. Global equity indices are generally higher.

2026. g. 9. jūl. 23:41 UTC

Macro News
Correlated Moves

Bitcoin rises to $63,300 amid improved sentiment from U.S.-Iran negotiations and falling crude oil prices, boosting risk assets including cryptocurrencies.

2026. g. 9. jūl. 23:36 UTC

Correlated Moves

The US 30Y Treasury Bond Index is higher during Thursday's session, reflecting a general upward movement since the previous close.

2026. g. 9. jūl. 23:36 UTC

Ulta Beauty Inc. shares advanced in after-market trading, despite no specific news. Market sentiment remains influenced by geopolitical tensions affecting oil prices.

2026. g. 9. jūl. 23:36 UTC

ETF Constituents

After-market trading for the Communication Services Select Sector SPDR Fund remains roughly flat, with slight declines from Netflix and Alphabet Inc. contributing to performance.

Salīdzinājums

Cenas izmaiņa

Zentalis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

36.17% augšup

Prognoze 12 mēnešiem

Vidējais 6.4 USD  36.17%

Augstākais 10 USD

Zemākais 4 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

6 ratings

3

Pirkt

3

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat